Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 5

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
ulated other comprehensive  Total   Number of shares  Amount  paid in capital  Accumulated deficit  (losses)/gain  stockholders’equity Balance as of December 31, 2023 *  1,766,766  $17,191,315  $(5,011,891) $(1,844,278) $(677,294) $9,657,852 Net loss for the period  -   -   -   (103,757)  -   (103,757)Foreign currency translation loss  -   -   -   -   (209,908)  (209,908)Balance as of March 31, 2024 *  1,766,766  $17,191,315  $(5,011,891) $(1,948,035) $(887,202) $9,344,187 Net profit for the period  -   -   -   199,104   -   199,104 Foreign currency translation gain  -   -   -   -   2,463   2,463 Balance as of June 30, 2024 *  1,766,766  $17,191,315  $(5,011,891) $(1,748,931) $(884,739) $9,545,754 Net loss for the period  -   -   -   (1,345,370)  -   (1,345,370)Issuance of shares  30,000   141,000               141,000 Foreign currency translation gain  -   -   -   -   1,046,789   1,046,789 Balance as of September 30, 2024 *  1,796,766  $17,332,315  $(5,011,891) $(3,094,301) $162,050  $9,388,173 

* Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 1-for-10 reverse stock split effected on April 7